Aardvark Therapeutics Reports Q4/FY25 Results, Provides Business Updates Following Phase 3 Trial Pause
AARD is trading near its 52-week low of $4.01 (3.2% above the low).
Summary
Aardvark Therapeutics has reported its fourth quarter and full year 2025 financial results, alongside providing business updates. This announcement comes shortly after the company disclosed a voluntary pause in enrollment and dosing for its Phase 3 HERO and OLE trials due to unexpected safety signals. For a small-cap biotech, these financial results are crucial, offering insight into the company's cash runway and operational sustainability in the wake of a significant clinical setback. Traders will be closely examining the financials and any further details within the business updates regarding the implications of the trial pause and the company's path forward for its pipeline.
At the time of this announcement, AARD was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88.5M. The 52-week trading range was $4.01 to $17.94. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.